In clinical trials.
Class/mechanism: Monovalent (one-armed) monoclonal antibody that binds to the extracellular Sema domain of c-Met and inhibits binding of hepatocyte growth factor (HGF). This interferes with ligand-dependent c-Met dimerization, activation of the intracellular kinase domain, and downstream signals that normally promote tumor proliferation, survival, and metastasis. The monovalent design was chosen to avoid potentially activating Met through dimerization of two Met molecules by onartuzumab.
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert.
- MetMab phase III clinical trial information: A Randomized, Phase III, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating Efficacy and Safety of Onartuzumab (Metmab) in Combination With Tarceva (Erlotinib) in Patients With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Standard Chemotherapy for Advanced/Metastatic Disease
Patient drug information
No information available.